tbuckley/cabot-search huggingface dataset:
Human Antimicrobial Peptides in Bodily Fluids: Current Knowledge and Therapeutic Perspectives in the Postantibiotic Era
Authors: Paulo Bastos, Fábio Trindade, João da Costa, Rita Ferreira, Rui Vitorino
Journal: Medicinal Research Reviews (2017)

ABSTRACT Antimicrobial peptides (AMPs) are an integral part of the innate immune defense mechanism of many organisms. Due to the alarming increase of resistance to antimicrobial therapeutics, a growing interest in alternative antimicrobial agents has led to the exploitation of AMPs, both synthetic and isolated from natural sources. Thus, many peptide‐based drugs have been the focus of increasing attention by many researchers not only in identifying novel AMPs, but in defining mechanisms of antimicrobial peptide activity as well. Herein, we review the available strategies for the identification of AMPs in human body fluids and their mechanism(s) of action. In addition, an overview of the distribution of AMPs across different human body fluids is provided, as well as its relation with microorganisms and infectious conditions.
Unmutated Immunoglobulin Heavy Chain Variable Region Genes and Disease Progression Post Splenectomy Are Poor Prognostic Factors in Splenic Marginal Zone Lymphoma.
Authors: David Graham Oscier, Sarah J. Mould, Anne C. Gardiner, Sharron Glide, Anton E. Parker, Zadie A. Davis, Jenny A. Orchard
Journal: Blood (2004)
Initiation of acute graft-versus-host disease by angiogenesis
Authors: Katarina Riesner, Yu Shi, Angela Jacobi, Martin Kräter, Martina Kalupa, Aleixandria McGearey, Sarah Mertlitz, Steffen Cordes, Jens-Florian Schrezenmeier, Jörg Mengwasser, Sabine Westphal, Daniel Perez-Hernandez, Clemens Schmitt, Gunnar Dittmar, Jochen Guck, Olaf Penack
Journal: Blood (2017)
Antibody-secreting plasma cells persist for decades in human intestine
Authors: Ole J.B. Landsverk, Omri Snir, Raquel Bartolomé Casado, Lisa Richter, Jeff E. Mold, Pedro Réu, Rune Horneland, Vemund Paulsen, Sheraz Yaqub, Einar Martin Aandahl, Ole M. Øyen, Hildur Sif Thorarensen, Mehran Salehpour, Göran Possnert, Jonas Frisén, Ludvig M. Sollid, Espen S. Baekkevold, Frode L. Jahnsen
Journal: The Journal of Experimental Medicine (2017)

Plasma cells (PCs) produce antibodies that mediate immunity after infection or vaccination. In contrast to PCs in the bone marrow, PCs in the gut have been considered short lived. In this study, we studied PC dynamics in the human small intestine by cell-turnover analysis in organ transplants and by retrospective cell birth dating measuring carbon-14 in genomic DNA. We identified three distinct PC subsets: a CD19+ PC subset was dynamically exchanged, whereas of two CD19- PC subsets, CD45+ PCs exhibited little and CD45- PCs no replacement and had a median age of 11 and 22 yr, respectively. Accumulation of CD45- PCs during ageing and the presence of rotavirus-specific clones entirely within the CD19- PC subsets support selection and maintenance of protective PCs for life in human intestine.
Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2.
Authors: Arturo Vega-Ruiz, Hagop Kantarjian, Jenny Shan, William Wierda, Jan Burger, Srdan Verstovsek, Guillermo Garcia-Manero, Jorge Cortes
Journal: Blood (2007)
Effects of Fluvastatin on the Expression of Tissue Factor Pathway Inhibitor in Human Umbilical Vein Endothelial Cells
Authors: Keiko Maruyama, Eriko Morishita, Hiroki Torishima, Akiko Sekiya, Hidesaku Asakura, Shigeki Ohtake, Shinji Nakao
Journal: Blood (2011)
Disrupting Wnt/ß-Catenin Signaling By a ß-Catenin/CBP Modulator C-82 Suppresses Cell Growth and Induces Apoptosis in AML Blasts and CD34+38- AML Progenitor Cells
Authors: Po Yee Mak, Steven M. Kornblau, Yihua Qiu, Wei Wei, Hiroyuki Kouji, Kevin Coombes, Jorge E. Cortes, Michael Andreeff, Bing Z Carter
Journal: Blood (2014)
Epstein-Barr Virus: Main Pathogenic Agent in Hodgkin Lymphoma Associated Hemophagocytic Syndrome?.
Authors: Fanny Menard, Caroline Besson, Patricia Rince, Olivier Lambotte, Thierry Lazure, Danielle Canioni, Olivier Hermine, Pierre Brousset, Claire Legendre, Antoine Martin, Philippe Gaulard, Martine Raphael, Claire Larroche
Journal: Blood (2007)
Effects of 5-Bromotetrandrine and Daunorubicin on the Expression of Survivin In K562/AO2 Cells
Authors: Bao-An Chen, Xiao-hui Cai, Jun Wang, Chong Gao, Jia-hua Ding, Jian Cheng, Yun-yu Sun, Hui-hui Song, Wen Bao, Ping-shen Chen, Yu Zhang, Meng Tang
Journal: Blood (2010)
Development of Essential Thrombocythemia-Like Myeloproliferative Disorder in Transgenic Mice Overexpressing a Human 8-Oxoguanine DNA-Glycosylase Gene.
Authors: Qin Huang, Haihong Zhang, Yubo Ma, Steven Schichman, Margie Scott, Lynn Doglio, Philip M. Iannacone, Lawrence M. Weiss, Chun-Yang Fan
Journal: Blood (2004)
Response by Hess et al to Letter Regarding Article, “Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program”
Authors: Paul L. Hess, Adrian F. Hernandez, Deepak L. Bhatt, Anne S. Hellkamp, Clyde W. Yancy, Lee H. Schwamm, Eric D. Peterson, Phillip J. Schulte, Gregg C. Fonarow, Sana M. Al-Khatib
Journal: Circulation (2017)
Allogeneic Stem Cell Transplantation (Allo-SCT) in Adults with Acute Myelogenous Leukemia (AML). Final Analysis of JALSG AML97 Study
Authors: Hisashi Sakamaki, Shuichi Miyawaki, Shigeki Ohtake, Nobuhiko Emi, Fumiharu Yagasaki, Kinuko Mitani, Shin Matsuda, Yuuji Kishimoto, Yasushi Miyazaki, Norio Asou, Masatomo Takahashi, Yoshiaki Ogawa, Sumihisa Honda, Ryuzo Ohno
Journal: Blood (2008)
Age-related differences pre-, intra-, and postcholecystectomy: A retrospective cohort study of 6,868 patients
Authors: Hadia Maqsood, Kalpesh Patel, Hamid Ferdosi, Anne M. Sill, Bin Wu, Thomas Buddensick, Amanda Sautter, Haroon Shaukat, Gisela Sulkowski, Dusty Marie Narducci, Mustafa Siddique, Farin Kamangar, Gopal C. Kowdley, Steven C. Cunningham
Journal: International Journal of Surgery (2017)
Enriching the Housing Environment for Mice Enhances Their NK Cell Antitumor Immunity via Sympathetic Nerve–Dependent Regulation of NKG2D and CCR5
Authors: Yanfang Song, Yu Gan, Qing Wang, Zihong Meng, Guohua Li, Yuling Shen, Yufeng Wu, Peiying Li, Ming Yao, Jianren Gu, Hong Tu
Journal: Cancer Research (2017)

Abstract Mice housed in an enriched environment display a tumor-resistant phenotype due to eustress stimulation. However, the mechanisms underlying enriched environment–induced protection against cancers remain largely unexplained. In this study, we observed a significant antitumor effect induced by enriched environment in murine pancreatic cancer and lung cancer models. This effect remained intact in T/B lymphocyte-deficient Rag1−/− mice, but was nearly eliminated in natural killer (NK) cell–deficient Beige mice or in antibody-mediated NK-cell–depleted mice, suggesting a predominant role of NK cells in enriched environment–induced tumor inhibition. Exposure to enriched environment enhanced NK-cell activity against tumors and promoted tumoral infiltration of NK cells. Enriched environment increased the expression levels of CCR5 and NKG2D (KLRK1) in NK cells; blocking their function effectively blunted the enriched environment–induced enhancement of tumoral infiltration and cytotoxic activity of NK cells. Moreover, blockade of β-adrenergic signaling or chemical sympathectomy abolished the effects of enriched environment on NK cells and attenuated the antitumor effect of enriched environment. Taken together, our results provide new insight into the mechanism by which eustress exerts a beneficial effect against cancer. Cancer Res; 77(7); 1611–22. ©2017 AACR.
Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC).
Authors: Alessandra Felici, Daniele Santini, Ugo De Giorgi, Michele De Tursi, Gaetano Facchini, Matteo Santoni, Elena Verzoni, Lisa Derosa, Giuseppe di Lorenzo, Giuseppe Badalamenti, Paolo Marchetti, Enrico Cortesi, Marco Maruzzo, Francesco Massari, Flavia Longo, Laura Noto, Joan Carles, Francesco Maria Guida, Isabella Sperduti, Michele Milella
Journal: Journal of Clinical Oncology (2014)

e15568 Background: With the exception of the Temsirolimus (Tem) registration trial, prRCC pts are grossly underrepresented in trials that have evaluated different therapeutic strategies. Methods: We collected information on a large cohort of prRCC pts (n=220) from 16 Italian and 1 Spanish centers. Results: Three main prognostic models (MSKCC, modified MSKCC - mMSKCC, International Metastatic RCC Database Consortium - DC) for a total of 8 individual risk factors (RF) were considered: the most frequent individual RF were multiple metastatic sites (87%), time from diagnosis to treatment (83%), anemia (76%), and KPS ≤70 (58%). According to MSKCC and DC, 61% and 63% of pts had prRCC, respectively, as compared to 89% using mMSKCC. mMSKCC criteria had the best discriminating power with a median OS of 30 mos (95% CI: 24-36 mos) for intermediate risk pts, as compared to 8 mos (95% CI: 7-9 mos) for truly prRCC (p<0.0001). Two hundred and seventeen pts received first-line treatment (VEGFR-TKI 70%, Tem 24%, other 4%). Second- and third-line therapy were administered in 44% and 13% of pts, respectively. After first-line treatment, the median number of RF was reduced from 4 to 3 (p<0.0001) and the percentage of prRCC was reduced from 92% to 86%, p=0.023, using the mMSKCC model. Median PFS and OS were 4 (95% CI: 3-5) and 9 (95% CI: 7-11) mos, respectively, for the entire population; overall DCR (PR and SD>6 mos) was 33% and was significantly higher for pts receiving first-line TKI versus Tem (40% vs 22%, p=0.02), while treatment was not significantly associated with ORR, PFS, or OS. Approximately 25% of prRCC pts survived longer than 12 mos, regardless of the type of treatment received. At multivariate analysis, type of first-line treatment and mMSKCC were predictive of DCR, mMSKCC was the only significant predictor of PFS, while number of RF, age, and mMSKCC were predictive of OS. Conclusions: Despite heterogeneity, prRCC may benefit from systemic treatment across multiple lines of therapy. Further prognostic stratification within the prRCC group is clearly necessary (see also the abstract by Santini et al. at this Meeting).
The Safety, Pharmacokinetics and Pharmacodynamics of KW-2478, a Novel Hsp90 Antagonist, in Patients with B-Cell Malignancies: A First-in-Man, Phase I, Multicentre, Open-Label, Dose Escalation Study
Authors: J. D. Cavenagh, K. Yong, J. Byrne, J. Cavet, P. Johnson, G. Morgan, C. Williams, S. Akinaga, G. Francis, J. Kilborn
Journal: Blood (2008)
Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.
Authors: Francisco Cervantes, Pilar López-Garrido, María-Isabel Montero, Fermín Jonte, Jesus Martinez, Juan-Carlos Hernández-Boluda, María Calbacho, Anna Sureda, Gloria Pérez-Rus, José Nieto, Cristina Pérez-López, José Román, Marcos González, Arturo Pereira, Dolors Colomer
Journal: Blood (2009)
TP53 Alterations Are Frequent in Patients over 60 Years with B-Precursor Acute Lymphoblastic Leukemia (ALL) and Low Hypodiploid/Near Triploid (HoTr) Karyotype; They Correlate with RB1 Deletion and Leukemic Telomere Gain
Authors: Ghada Zakout, Lena Rai, Anthony V. Moorman, Adele K. Fielding
Journal: Blood (2014)
The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial
Authors: Alan K. Burnett, Robert K. Hills, Lone S. Friis, Lars Kjeldsen, Donald Milligan, Ann E. Hunter, Michelle Lazenby, Amanda F Gilkes, David Bowen, Nigel Russell
Journal: Blood (2013)
Expression of WT1, Survivin, and TERT genes in Acute Myeloid Leukemia: Important Clinical Prognostic Indicators Envisioning Triple Immunotherapeutic Targets.
Authors: Heeje Kim, Hee-Baeg Choi, Tai-Hyang Lee, Hyun-Jung Sohn, Tai-Gyu Kim, Woo-Sung Min
Journal: Blood (2009)
Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model
Authors: Anastassia Karageorgis, Michaël Claron, Romain Jugé, Caroline Aspord, Fabien Thoreau, Claire Leloup, Jérôme Kucharczak, Joël Plumas, Maxime Henry, Amandine Hurbin, Pascal Verdié, Jean Martinez, Gilles Subra, Pascal Dumy, Didier Boturyn, Abdel Aouacheria, Jean-Luc Coll
Journal: Molecular Therapy (2017)

Melanoma is a highly metastatic and deadly form of cancer. Invasive melanoma cells overexpress integrin αvβ3, which is a well-known target for Arg-Gly-Asp-based (RGD) peptides. We developed a sophisticated method to synthetize milligram amounts of a targeted vector that allows the RGD-mediated targeting, internalization, and release of a mitochondria-disruptive peptide derived from the pro-apoptotic Bax protein. We found that 2.5 μM Bax[109-127] was sufficient to destabilize the mitochondria in ten different tumor cell lines, even in the presence of the anti-apoptotic Bcl2 protein, which is often involved in tumor resistance. This pore-forming peptide displayed antitumor activity when it was covalently linked by a disulfide bridge to the tetrameric RAFT-c[RGD]4-platform and after intravenous injection in a human melanoma tumor model established in humanized immuno-competent mice. In addition to its direct toxic effect, treatment with this combination induced the release of the immuno-stimulating factor monocyte chimoattractant protein 1 (MCP1) in the blood and a decrease in the level of the pro-angiogenic factor FGF2. Our novel multifunctional, apoptosis-inducing agent could be further customized and assayed for potential use in tumor-targeted therapy.
Dynamic Changes in Platelet Responsiveness to Thrombin and Coated Platelet Potential May Inform Risk of Hemorrhage and/or Thrombosis in a Novel Canine Mode of Immune Thrombocytopenia.
Authors: Marshall A. Mazepa, Dana N LeVine, Adam J Birkenheuer, Marjory B Brooks, Shila K Nordone, Dwight A Bellinger, Sam L Jones, Thomas H Fischer, Jonathan E Fogle, Nigel S Key
Journal: Blood (2012)
Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas
Authors: Maeva Dufies, Sandy Giuliano, Damien Ambrosetti, Audrey Claren, Papa Diogop Ndiaye, Michalis Mastri, Walid Moghrabi, Lindsay S. Cooley, Marc Ettaiche, Emmanuel Chamorey, Julien Parola, Valerie Vial, Marilena Lupu-Plesu, Jean Christophe Bernhard, Alain Ravaud, Delphine Borchiellini, Jean-Marc Ferrero, Andréas Bikfalvi, John M. Ebos, Khalid Saad Khabar, Renaud Grépin, Gilles Pagès
Journal: Cancer Research (2017)

Sunitinib is an antiangiogenic therapy given as a first-line treatment for renal cell carcinoma (RCC). While treatment improves progression-free survival, most patients relapse. We hypothesized that patient relapse can stem from the development of a lymphatic network driven by the production of the main growth factor for lymphatic endothelial cells, VEGFC. In this study, we found that sunitinib can stimulate vegfc gene transcription and increase VEGFC mRNA half-life. In addition, sunitinib activated p38 MAPK, which resulted in the upregulation/activity of HuR and inactivation of tristetraprolin, two AU-rich element-binding proteins. Sunitinib stimulated a VEGFC-dependent development of lymphatic vessels in experimental tumors. This may explain our findings of increased lymph node invasion and new metastatic sites in 30% of sunitinib-treated patients and increased lymphatic vessels found in 70% of neoadjuvant treated patients. In summary, a therapy dedicated to destroying tumor blood vessels induced the development of lymphatic vessels, which may have contributed to the treatment failure. Cancer Res; 77(5); 1212-26. ©2017 AACR.
The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group
Authors: Torsten Haferlach, Alexander Kohlmann, Giuseppe Basso, Marie-Christine Béné, Sabina Chiaretti, James R. Downing, Jesús-María Hernández, Wolf-Karsten Hofmann, Thomas J. Kipps, Evelyn S Koay, Geertruy Te Kronnie, Wei-min Liu, Elizabeth MacIntyre, Ken I Mills, Peter Papenhausen, Claude Preudhomme, Laura Z Rassenti, Sheila A Shurtleff, John De Vos, Allen E Yeoh, P. Mickey Williams, Lothar Wieczorek, Robert Foà
Journal: Blood (2008)
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group Trial (E3205)
Authors: Madhur K. Garg, Fengmin Zhao, Joseph A. Sparano, Joel Palefsky, Richard Whittington, Edith P. Mitchell, Mary F. Mulcahy, Karin I. Armstrong, Nassim H. Nabbout, Shalom Kalnicki, Bassel F. El-Rayes, Adedayo A. Onitilo, Daniel J. Moriarty, Thomas J. Fitzgerald, Al B. Benson
Journal: Journal of Clinical Oncology (2017)

Purpose Squamous cell carcinoma of the anal canal (SCCAC) is characterized by high locoregional failure (LRF) rates after sphincter-preserving definitive chemoradiation (CRT) and is typically associated with anogenital human papilloma virus infection. Because cetuximab enhances the effect of radiation therapy in human papilloma virus–associated oropharyngeal squamous cell carcinoma, we hypothesized that adding cetuximab to CRT would reduce LRF in SCCAC. Methods Sixty-one patients with stage I to III SCCAC received CRT including cisplatin, fluorouracil, and radiation therapy to the primary tumor and regional lymph nodes (45 to 54 Gy) plus eight once-weekly doses of concurrent cetuximab. The study was designed to detect at least a 50% reduction in 3-year LRF rate (one-sided α, 0.10; power 90%), assuming a 35% LRF rate from historical data. Results Poor risk features included stage III disease in 64% and male sex in 20%. The 3-year LRF rate was 23% (95% CI, 13% to 36%; one-sided P = .03) by binomial proportional estimate using the prespecified end point and 21% (95% CI, 7% to 26%) by Kaplan-Meier estimate in a post hoc analysis using methods consistent with historical data. Three-year rates were 68% (95% CI, 55% to 79%) for progression-free survival and 83% (95% CI, 71% to 91%) for overall survival. Grade 4 toxicity occurred in 32%, and 5% had treatment-associated deaths. Conclusion Although the addition of cetuximab to chemoradiation for SCCAC was associated with lower LRF rates than historical data with CRT alone, toxicity was substantial, and LRF still occurs in approximately 20%, indicating the continued need for more effective and less toxic therapies.
Long-Term Follow-Up of Recombinant Human Erythropoietin (epoetin)Induced Pure Red Cell Aplasia (PRCA): A Comparison of Data Collected through Active and Passive Pharmacovigilance Efforts.
Authors: Charles L. Bennett, Kenneth R. Carson, June M. McKoy, Steven M. Belknap, Stephen A. Klinge, Andrew M. Evens, Dennis W. Raisch, Paul R. Yarnold, Benjamin Kim, Elizabeth A. Lyons, Timothy K. Kuzel, Martin S. Tallman
Journal: Blood (2004)
Protective Effects of Pentoxyfilline In Renal Toxicity After Methotrexate Administration
Authors: Iraj Asvadi Kermani, Babak Hajipour, Atabak Asvadi Kermani, Naser Ahmadi Asl, Leila Roshanghar, Ali Khodadadi, Kamran Alimoghaddam
Journal: Blood (2010)
Vectorcardiographic Studies in Acquired Valvular Disease
Authors: H. TOSHIMA, J. CUETO, C. WALTON LILLEHEI
Journal: Circulation (1967)

A vectorcardiographic study using the Schmitt-Simonsen (SVEC-III) method was done in 92 patients with mitral and aortic acquired valvular disease in which left ventricular hypertrophy and the valvular lesions were proven by means of right and left heart catheterization, operation, or autopsy, or by all methods. Significant differences were found among groups with aortic insufficiency, aortic stenosis, and mitral insufficiency. The magnitude of the 0.01 and 0.02-sec and maximal spatial vectors and the voltages of the Q x , R x , as well as R z waves were greatest in the group with aortic insufficiency. The greatest voltages of the 0.03-sec and 0.04-sec vectors were found in patients with aortic stenosis. In this study the smaller voltages after the 0.03-sec vector were found in the group with mitral insufficiency, and these voltages were significantly increased when aortic insufficiency complicated the picture. Groups with aortic insufficiency and mitral insufficiency, or aortic stenosis or insufficiency and mitral stenosis showed abnormal inferior orientation of the middle and terminal forces, which were explained upon the basis of the concomitant right ventricular hypertrophy. The authors believe that with the aid of the corrected orthogonal system of Schmitt and Simonsen (SVEC-III) the clinician will be able not only to make a more accurate evaluation of left ventricular hypertrophy, but also in many instances will find considerable assistance in arriving at a specific clinical diagnosis.
Surgical Treatment for Acute Type A Aortic Dissection in Pregnancy:- A Case of Aortic Root Replacement Just After Cesarean Section -
Authors: Hidetoshi Akashi, Keiichiro Tayama, Takayuki Fujino, Seiji Onitsuka, Hideki Sakashita, Shigeaki Aoyagi
Journal: Circulation (2000)

A 25-year-old woman with Marfan syndrome in the 37th week of pregnancy was referred for acute chest pain and dyspnea. An emergency Cesarean section was performed because of fetal distress. Intraoperative echocardiography at the end of the Cesarean section showed dilatation of the aortic root and dissection of the ascending aorta. The patient underwent replacement of the aortic root and the ascending aorta on the following day because of uterine bleeding. The postoperative course was uneventful for the mother and her baby.
Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL)
Authors: Marta Coscia, Michela Capello, Valentina Griggio, Federica Linty, Candida Vitale, Silvia Peola, Barbara Castella, Micol Rigoni, Daniela Drandi, Marina Ruggeri, Paola Omedè, Marco Ladetto, Franco Novelli, Mario Boccadoro, Massimo Massaia
Journal: Blood (2010)
Non-Myeloablative Allogeneic Stem Cell Transplantation in 154 Patients (pts) with Chronic Myeloid Leukaemia (CML).
Authors: Malek Benakli, Rose-Marie Hamladji, Redhouane Ahmed Nacer, Amina Talbi, Farih Mehdid, Rachida Belhadj, Nadia Rahmoune
Journal: Blood (2007)
Analysis of NK Cells Receptors and NK Cells Ligands in Acute Myeloid Leukemia: Comparisons Between the Blood and the Bone Marrow.
Authors: Jerome Rey, Eloise Perrot, Caroline Veuillen, Thomas Prébet, Anne Etienne, Aude Charbonnier, Evelyne D'Incan, Norbert Vey, Daniel Olive
Journal: Blood (2009)
Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma
Authors: John H. Chen, Daniel J. Lenihan, Sharon E. Phillips, Madan H. Jagasia, Stacey A. Goodman, Adetola A. Kassim, Shelton L. Lacy, Kevin T. McDonagh, Javid J. Moslehi, Tarsheen K. Sethi, David A. Slosky, Oluchi C. Ukaegbu, Robert F. Cornell
Journal: Blood (2015)
Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry
Authors: Maria Teresa Voso, Pasquale Niscola, Alfonso Piciocchi, Livio Pagano, Luca Maurillo, Pellegrino Musto, Luana Fianchi, Giovanna Mansueto, Antonietta Aloe-Spiriti, Francesco Buccisano, Adriano Venditti, Andrea Tendas, Stefano Mancini, Anna Lina Piccioni, Alessandro Andriani, Roberto Latagliata, Giuliana Alimena, Nunzio Filardi, Alberto Fragasso, Agostino Tafuri, Susanna Fenu, Massimo Breccia
Journal: Blood (2014)
Alemtuzumab as Consolidation after a Response to Fludarabine Is Effective To Purge Residual Disease in Patients with Chronic Lymphocytic Leukemia.
Authors: Marco Montillo, Alessandra Tedeschi, Valentina Rossi, Anna Maria Cafro, Roberto Cairoli, Silvio Veronese, Barbara Scarpati, Renata Farioli, Mario Regazzi, Marcello Gambacorta, Enrica Morra
Journal: Blood (2004)